Stock listing

Innovent Biologics, Inc.

Selected listing: 1801 · HKEX · HKD · HK

Innovent Biologics, Inc. (HKEX:1801), Health Technology. Latest release Sep 29, 2026: 2026 INTERIM REPORT.

1801:HKEXHKDHKUpdated October 2, 2026

Ticker: HKEX:1801
Asset type: Stock
Sector: Health Technology
Industry: Pharmaceuticals: Major
Exchange: HKEX
Currency: HKD

About Innovent Biologics, Inc.

Innovent Biologics, Inc. is a public company listed on the Hong Kong stock exchange under the ticker 1801. Innovent focuses on the development and commercialization of innovative biologics for the treatment of various diseases.

Latest news from Innovent Biologics, Inc.

2026 INTERIM REPORT

September 29, 2026

VOLUNTARY ANNOUNCEMENT - JAYPIRCA (PIRTOBRUTINIB) APPROVED IN CHINA FOR A NEW INDICATION IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL) ACROSS ALL LINES OF THERAPY

September 28, 2026

Innovent Announces Expansion of Global Phase 3 MarsLight-11 Study of IBI363/TAK-928 (Alpha-biased IL-2/PD-1 Bispecific Fusion Protein) in Immunotherapy-Resistant NSCLC to Include Patients with Non-Squamous NSCLC

September 27, 2026

Altruist Biologics' Suzhou Site Receives EMA GMP Certification, Enabling Product Commercialization for the European Market

September 22, 2026

Innovent Announces 2026 Interim Results and Business Updates

August 25, 2026

All Innovent Biologics, Inc. news →

Research Innovent Biologics, Inc.

Innovent Biologics, Inc. company profile

View the public company page for Innovent Biologics, Inc. on 6ix.

Innovent Biologics, Inc. news

Read company news and market updates connected to Innovent Biologics, Inc..

Innovent Biologics, Inc. investor events

Find investor webinars, events, and replay context for Innovent Biologics, Inc..